Work

CLL-179: Real-World Pharmacovigilance Assessment of Hematologic Safety Signals Among Bruton Tyrosine Kinase Inhibitors, Including Pirtobrutinib: Insights From the Food and Drug Administration Adverse Event Reporting System

Year: 2026

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)02021-5

Authors: Quoc Hoang Pham, Klesta Cocoli, Hammad Assilkhi, Haniyah Gul, Sima Jabri, Nour Elghoul, Shreya Singh Beniwal, Anushka Anand Hanchate

Institutions: International University of Health and Welfare Narita Hospital, New York Medical College, Altınbaş University, Foundation University Islamabad, Foundation University Medical College, Qatar University, Lady Hardinge Medical College, Mahatma Gandhi Memorial Medical College

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7204732465

Cites:

Cited by:

Related to: 10